TransCode Therapeutics, Inc. (RNAZ) Narx-foyda multiplikatori

TransCode Therapeutics, Inc. - RNAZ emitenti grafik logotipi

TransCode Therapeutics (RNAZ) saraton uchun RNA dori yetkazib berish tizimiga ega eksklyuziv huquqlari va davlat agentliklari orasidagi ta'siri tufayli mustahkam pozitsiyani saqlab qolmoqda, shu bilan birga separate_pe ko'rsatkichi -0.60 darajasida turibdi. Ushbu grafikdagi tasdiqlangan narxlar tarixi ulkan sinov xarajatlari va ilmiy tadqiqotlarning murakkabligi bo'yicha ma'lumotlar bilan to'ldirilgan. Joriyligi muvaffaqiyat nanoparticlesga asoslangan, biroq biznesning uzoq muddatli barqarorligi insonlar ustida o'tkazilayotgan sinovlarning yakuniy natijalariga bog'liq.

transcodetherapeutics.com (RNAZ) P/E multiplikatori: 04.07.2022 - 10.11.2026 davri uchun

TransCode Therapeutics Inc. (RNAZ) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi TransCode|RNAZ - Maqsadli narxlar grafigi
- bozor kapitallashuvi tafsilotlari:
Bozor kapitallashuvi TransCode Therapeutics, Inc.|RNAZ - Kompaniyaning to‘liq qiymati
- emitentning balans qiymati statistikasi:
Aksiya hisobiga sof aktivlar TransCode Therapeutics|RNAZ - Balans kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati transcodetherapeutics.com|RNAZ - Kompaniyaning jami aktivlari
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati TransCode Therapeutics|RNAZ - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi TransCode|RNAZ - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar TransCode Therapeutics, Inc.|RNAZ - Kompaniyaning uzoq muddatli majburiyatlari|Kompaniyaning qisqa muddatli kredit va qarzlari TransCode Therapeutics|Oraliq likvidlik koeffitsiyenti transcodetherapeutics.com
- foyda va bozor multiplikatorlari tafsilotlari:
RNAZ - Sof foyda|Kutilayotgan sof daromad TransCode Therapeutics|RNAZ - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati TransCode|RNAZ - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati TransCode Therapeutics, Inc.|RNAZ - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) TransCode Therapeutics|RNAZ - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik dinamikasi transcodetherapeutics.com|RNAZ - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi TransCode Therapeutics
Kompaniyaning jamlanma tahlili:RNAZ (transcodetherapeutics.com)
transcodetherapeutics.com original mahsuloti

TransCode Therapeutics (RNAZ) onkologik kasalliklar uchun innovatsion RNK terapiya usullariga e'tibor qaratadi. Bozor kapitalizatsiyasining sof foydaga nisbati emitentning joriy daromadlarining bir dollari qiymatini belgilaydi. Investorlar ushbu koeffitsiyentdan aktivning haqiqiy daromadiga nisbatan haddan tashqari sotib olinganligini baholash uchun foydalanadilar. Tijorat daromadlari yo'qligi va yuqori R&D xarajatlarini hisobga olgan holda, ushbu metrika ko'pincha manfiy qiymatga ega bo'ladi. TransCode Therapeutics (RNAZ) ning fundamental P/E koeffitsiyentini tahlil qilish orqali joriy kotirovkalardagi spekulyatsiyaning darajasini baholash mumkin.

Raqobatdosh kompaniyalar

P/E multiplikatori Tempus AI Inc|Narxning foydaga nisbati Qiagen (QGEN)|Ionis Pharmaceuticals, Inc. - Narx-foyda multiplikatori|Narxning foydaga nisbati Repligen Corp. RGEN|Biznesning o‘zini qoplash muddati Avidity Corp (RNA)|CRISPR Therapeutics AG - P/E multiplikatori|genedx.com (WGS) - Narx-foyda koeffitsiyenti|Ultragenyx (RARE) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Beam Therapeutics Inc (BEAM)|SRPT (Sarepta Therapeutics Inc) - P/E multiplikatori|Narx-foyda multiplikatori TWST (Twist Bioscience Corp)|P/E multiplikatori TXG|NTLA - Kapitalizatsiyaning foydaga nisbati|Stoke Therapeutics, Inc. - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati BLFS|WVE: Narx-foyda koeffitsiyenti|Maze Therapeutics Corp - Bozor narxining sof foydaga nisbati|SION: P/E multiplikatori|primemedicine.com - Kompaniya qiymatining sof foydaga nisbati|TSHA (Taysha Gene Therapies, Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati uniQure NV QURE|Narxning foydaga nisbati MeiraGTx PLC (MGTX)|RGNX (REGENXBIO Corp) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori SLDB (Solid Biosciences Inc.)|P/E multiplikatori ocugen.com OCGN|PACB - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati BNTC|DSGN: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Rocket Corp (RCKT)|Narx-foyda koeffitsiyenti FDMT|P/E multiplikatori Lexeo|Narx-foyda koeffitsiyenti KRRO (Korro Bio, Inc.)|Bozor narxining sof foydaga nisbati EDIT|P/E multiplikatori SLN (Silence Therapeutics Inc.)|Biznesning o‘zini qoplash muddati ProQR (PRQR)|Codexis Bio - P/E multiplikatori|sangamo.com (SGMO) - Narx-foyda koeffitsiyenti|nautilus.bio (NAUT) - Narxning foydaga nisbati|MGX - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Precision BioSciences, Inc.|GBIO: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Boundless Bio, Inc. (BOLD)|exicuretx.com - Narx-foyda multiplikatori|P/E multiplikatori IMNN (Imunon)|P/E multiplikatori Phio Pharmaceuticals Corp PHIO|MBIO: Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati BNGO|APDN: P/E multiplikatori|Narx-foyda multiplikatori BLUE|Narxning foydaga nisbati ImmunoPrecise Antibodies Ltd|Narx-foyda multiplikatori OMGA (Omega Therapeutics Inc)|P/E multiplikatori OMIC|P/E multiplikatori Regulus (RGLS)|Syros Pharmaceuticals - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati TBIO (telesisbio.com)|TCON - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati UBX (Unity Biotechnology Inc.)